《瑞德西韦的修正：对其发现与研发历程的回顾，该历程导向了针对治疗 COVID-19 的人体临床试验》
Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19.
作者信息
Eastman Richard T, Roth Jacob S, Brimacombe Kyle R, Simeonov Anton, Shen Min, Patnaik Samarjit, Hall Matthew D
出版信息
ACS Cent Sci. 2020 Jun 24;6(6):1009. doi: 10.1021/acscentsci.0c00747. Epub 2020 Jun 16.
Abstract
[This corrects the article DOI: 10.1021/acscentsci.0c00489.].
摘要
[本文更正了文章的数字对象标识符：10.1021/acscentsci.0c00489。]
相似文献
1
Correction to Remdesivir: A Review of Its Discovery and Development Leading to Human Clinical Trials for Treatment of COVID-19.《瑞德西韦的修正：对其发现与研发历程的回顾，该历程导向了针对治疗 COVID-19 的人体临床试验》
ACS Cent Sci. 2020 Jun 24;6(6):1009. doi: 10.1021/acscentsci.0c00747. Epub 2020 Jun 16.
2
The journey of remdesivir: from Ebola to COVID-19.瑞德西韦的历程：从埃博拉到新冠病毒。
Drugs Context. 2020 May 22;9. doi: 10.7573/dic.2020-4-14. eCollection 2020.
3
Correction to "An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with Efficacy against Drug-Resistant Gram-Negative Infections".对《一种迭代方法指导法比霉素（FabI抑制剂，一种对耐药革兰氏阴性感染有效的后期抗生素候选药物）的发现》的修正
ACS Cent Sci. 2022 Sep 28;8(9):1362. doi: 10.1021/acscentsci.2c00969. Epub 2022 Sep 6.
4
Correction to "Molecular Caging of Graphene with Cyclohexane: Transfer and Electrical Transport".《环己烷对石墨烯的分子封装：转移与电输运》的更正
ACS Cent Sci. 2018 May 23;4(5):661. doi: 10.1021/acscentsci.8b00227. Epub 2018 Apr 25.
5
Correction to Chemical Fingerprint of Zn-Hydroxyapatite in the Early Stages of Osteogenic Differentiation.成骨分化早期锌羟基磷灰石化学指纹图谱的修正
ACS Cent Sci. 2019 Oct 23;5(10):1731. doi: 10.1021/acscentsci.9b00918. Epub 2019 Oct 15.
6
Correction to Rational Design of Fluorogenic and Spontaneously Blinking Labels for Super-Resolution Imaging.《用于超分辨率成像的荧光和自发闪烁标记的合理设计》的更正
ACS Cent Sci. 2020 Oct 28;6(10):1844. doi: 10.1021/acscentsci.0c01119. Epub 2020 Sep 16.
7
Correction to "Synthetic Elaboration of Native DNA by RASS (SENDR)".对《通过RASS（SENDR）进行天然DNA的合成加工》的修正
ACS Cent Sci. 2020 Nov 25;6(11):2117. doi: 10.1021/acscentsci.0c01389. Epub 2020 Oct 23.
8
Correction to "Assessing Physicochemical Properties of Drug Molecules via Microsolvation Measurements with Differential Mobility Spectrometry".对《通过差分迁移谱微溶剂化测量评估药物分子的物理化学性质》的修正
ACS Cent Sci. 2017 Apr 26;3(4):359. doi: 10.1021/acscentsci.7b00106. Epub 2017 Mar 15.
9
Correction to Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial.《用冷响应纳米材料克服卵巢癌耐药性》的更正
ACS Cent Sci. 2021 May 26;7(5):909. doi: 10.1021/acscentsci.1c00530. Epub 2021 May 17.
10
Correction to "Accurate Representations of the Microphysical Processes Occurring during the Transport of Exhaled Aerosols and Droplets".对《呼出气溶胶和飞沫传输过程中发生的微物理过程的准确表述》的勘误
ACS Cent Sci. 2021 Mar 24;7(3):507. doi: 10.1021/acscentsci.1c00220. Epub 2021 Feb 26.
引用本文的文献
1
Exploring TMPRSS2 Drug Target to Combat Influenza and Coronavirus Infection.探索跨膜丝氨酸蛋白酶2药物靶点以对抗流感和冠状病毒感染。
Scientifica (Cairo). 2025 Apr 21;2025:3687892. doi: 10.1155/sci5/3687892. eCollection 2025.
2
Universal and divergent P-stereogenic building with camphor-derived 2,3-diols.具有樟脑衍生的2,3-二醇的通用且多样的P-手性结构单元。
Commun Chem. 2023 Jun 27;6(1):133. doi: 10.1038/s42004-023-00935-0.
3
Antiviral Lipid Nanocarrier Loaded with Remdesivir Effective Against SARS-CoV-2 in vitro Model.载有瑞德西韦的抗病毒脂质纳米载体在体外模型中对 SARS-CoV-2 有效。
Int J Nanomedicine. 2023 Mar 27;18:1561-1575. doi: 10.2147/IJN.S391462. eCollection 2023.
4
Inhibition of Human Coronaviruses by Combinations of Host-Targeted and Direct-Acting Antivirals.宿主靶向和直接作用抗病毒药物联合抑制人冠状病毒。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0170322. doi: 10.1128/aac.01703-22. Epub 2023 Mar 28.
5
Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets.宿主细胞和 SARS-CoV-2 相关的分子结构和因素作为潜在的治疗靶点。
Cells. 2021 Sep 15;10(9):2427. doi: 10.3390/cells10092427.
6
Encapsulated hydroxychloroquine and chloroquine into cyclic oligosaccharides are the potential therapeutics for COVID-19: insights from first-principles calculations.将羟氯喹和氯喹包裹于环状低聚糖中是治疗新冠肺炎的潜在疗法：基于第一性原理计算的见解
J Mol Struct. 2022 Jan 5;1247:131371. doi: 10.1016/j.molstruc.2021.131371. Epub 2021 Aug 26.
7
Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-analysis.瑞德西韦治疗新型冠状病毒肺炎的疗效和安全性评估：一项荟萃分析。
SN Compr Clin Med. 2021;3(12):2443-2454. doi: 10.1007/s42399-021-01014-y. Epub 2021 Aug 7.
8
Analysis of COVID-19 on Diagnosis, Vaccine, Treatment, and Pathogenesis with Clinical Scenarios.COVID-19的诊断、疫苗、治疗及发病机制与临床案例分析
Clin Pract. 2021 May 19;11(2):309-321. doi: 10.3390/clinpract11020044.
9
Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells.腺苷相关的小分子通过回忆抗原检测筛选化合物对记忆 T 细胞的脱靶作用具有实用性。
Sci Rep. 2021 May 5;11(1):9561. doi: 10.1038/s41598-021-88965-3.
10
Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.用于治疗 COVID-19 的候选药物的药物相互作用：概述。
Pharmacol Res Perspect. 2021 Feb;9(1):e00705. doi: 10.1002/prp2.705.
本文引用的文献
1
Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.埃博拉病毒在非人灵长类动物中的动态变化为研究病毒的免疫发病机制和抗病毒策略提供了线索。
Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.
2
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.冠状病毒对抗病毒药物瑞德西韦（GS-5734）的易感性是由病毒聚合酶和校对核糖核酸外切酶介导的。
mBio. 2018 Mar 6;9(2):e00221-18. doi: 10.1128/mBio.00221-18.
3
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.小分子GS-5734对恒河猴体内埃博拉病毒的治疗效果。
Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2.
Zotero 插件